Navigation Links
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Date:2/27/2008

have had no treatment options, as patients in the clinical trial on everolimus experienced a significantly longer period of time during which their cancer did not progress," said Daniel Vasella, Chairman and CEO of Novartis. "Everolimus is a targeted therapy which is being studied in multiple tumor types, and could provide significant benefit to patients suffering from cancer."

"This progression-free survival benefit demonstrates the possibilities of continuous mTOR inhibition as a promising target in oncology," said David Epstein, President and CEO, Novartis Oncology. "These data are the first from a broad clinical research program that includes studies in patients with high unmet needs suffering from a variety of cancers. Everolimus is the first compound in our dynamic oncology late-stage pipeline with six compounds in registration trials to show exciting clinical data this year."

Complete results of the RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) trial will be submitted as a late-breaking abstract for presentation at the American Society of Clinical Oncology annual meeting in May. Worldwide regulatory filings for this indication beginning with US and EU will occur in the second half of 2008.

RECORD-1 is the largest Phase III trial to investigate the potential of the oral mTOR inhibitor everolimus as a treatment option for patients with metastatic RCC who have failed prior targeted therapy. The randomized, double- blind multi-center Phase III study compared everolimus to placebo.

Patients in the study were randomized according to Memorial Sloan- Kettering Cancer Center (MSKCC) risk criteria and prior anti-cancer therapy. MSKCC risk criteria are standard clinical criteria to determine the prognosis of patients with RCC.

In addition to RCC, everolimus is presently being evaluated in neuroendocrine tumors, lymphoma, other cancers, and tuberous sclerosis as a single agent or in combination with existing cance
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
6. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Mass. , July 24, 2014   Royal ... today announced that it has received 510(k) clearance from ... innovative ultra mobile ultrasound system, VISIQ, in the U.S. ... to combine the benefits of greater mobility, performance and ... access to quality diagnostic scans for more OB patients. ...
(Date:7/24/2014)... 24, 2014 Second Quarter and ... and Chief Executive Officer effective September 2, 2014 ... million , BioGlue ® revenues grew 14 ... revenues grew 22 percent year-over-year to $1.1 million ... percent year-over-year to $1.7 million , Tissue processing ...
(Date:7/24/2014)... July 24, 2014  Bayer HealthCare today announced ... evaluated a 15% foam formulation of its compound ... inflammatory papules and pustules of rosacea. An AzA ... complement the currently available AzA gel formulation. Papulopustular ... (papules and pustules) as well as erythema (redness) ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 2Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 3
... nContact, Inc., the leading innovator in epicardial ablation ... websites, www.ncontactinc.eu and www.ncontactinc.com . The ... of nContact,s technology and the market for treating cardiac ... "The new websites are excellent educational references that highlight ...
... 2011 Galleon Pharmaceuticals, a leader in the pharmaceutical ... of directors has elected Thomas J. Dietz, Ph.D., as ... of Waypoint Holdings, LLC, a diversified financial-holdings and services ... co-CEO and then CEO and a director of Pacific ...
Cached Medicine Technology:nContact, Inc. Launches New Corporate Websites 2Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2
(Date:7/24/2014)... can be reduced by enabling patients to see the ... This is just one of several recommendations made in ... University of Bristol. , Called ,Primary care factors and ... report has been compiled by researchers from the University,s ... from studies around the world. They found that patients ...
(Date:7/24/2014)... American air and missile defense radar market has been estimated ... a CAGR of 9.64% to reach $340 million by 2020. ... drug trafficking. Brazil is the only market in the region ... radar market. This is followed by Argentina and Chile, which ... in terms of costal surveillance and other air defense radar. ...
(Date:7/24/2014)... July 24, 2014 Dr. Peter Oettgen, ... Deaconess Medical Center in Boston, is the new Deputy ... Oettgen brings his considerable experience in the field to ... . , Dr. Oettgen received his medical degree ... completed his residency at Tufts New England Medical Center. ...
(Date:7/24/2014)... July 24, 2014 Boston Children’s Museum ... Sky, funded by NASA and created through a partnership ... The exhibit is an immersive and inspiring traveling exhibit ... 10, in early investigations of astronomical science. It ... includes a tour of the universe, reveals secrets of ...
(Date:7/24/2014)... protein p53 refers to cancer biology, and the functions ... described in detail. Furthermore, also in cancer biology, it ... tumour cells in order to block their metabolism and ... innovative research on p53 attempts to unveil its functions ... healthy cells. Recent studies with cell cultures have demonstrated ...
Breaking Medicine News(10 mins):Health News:Seeing the same GP at every visit will reduce emergency department attendance 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 3Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 4Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 5Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 2Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 3Health News:My Sky Exhibit Opens at Boston Children’s Museum 2Health News:My Sky Exhibit Opens at Boston Children’s Museum 3Health News:My Sky Exhibit Opens at Boston Children’s Museum 4Health News:My Sky Exhibit Opens at Boston Children’s Museum 5Health News:Identified a key molecule in flies that adjusts energy use under starvation conditions 2
... to develop malignancies after radiation treatments , , MONDAY, Feb. ... the success of childhood cancer treatments, researchers report that ... Hodgkin,s disease were almost 40 times more likely to ... cure most patients now who have Hodgkin,s disease. Back ...
... more headaches, new study suggests , , MONDAY, Feb. 16 (HealthDay ... naps to sleep it off, but they run the risk ... perpetuating the cycle of headaches, a new study shows. , ... tried to treat their headaches, and they rated it a ...
... members step down to become observers -SAN DIEGO, ... of wireless, handheld barcode point-of-care (BPOC) solutions ... Laub, Chief Executive Officer of Policy Studies ... Board of Directors. (Logo: http://www.newscom.com/cgi-bin/prnh/20090121/LA60632LOGO )" ...
... AUSTIN, Texas, Feb. 16 In 2007, Bedrest Fitness ... program. The first of its kind, Bedrest Fitness ... or restricted activity can perform to help maintain muscle strength and tone. ... Ejercicios Para ...
... MYL ) announced today that it will host ... 2009, at 5:00 p.m. ET to review the company,s financial ... Mylan will release its financial results on February 19 ... 19 call is 888-287-5536 or 719-325-2126 for international callers. ...
... often deserving 2009 SSI Disability cases will not ... of mistakes made on the disability application. The ... disabled consumers to take additional time ensuring they ... and submitted the proper supporting medical evidence. This ...
Cached Medicine News:Health News:Hodgkin's Survivors Prone to Breast Cancer Later 2Health News:Hodgkin's Survivors Prone to Breast Cancer Later 3Health News:Using Sleep to Manage Headaches May Cause Insomnia 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 3Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 2Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 3Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 4Health News:Spanish Exercise DVD Helps Latinas Reduce Risk of Preterm Labor 2Health News:SSI Disability Application Tips for 2009 2Health News:SSI Disability Application Tips for 2009 3Health News:SSI Disability Application Tips for 2009 4Health News:SSI Disability Application Tips for 2009 5
... evaluation of pancreatic -cell function is not only ... of the natural history of diabetes mellitus, but ... guide to the correct choice of treatment. Peripheral ... function because of the large and variable uptake ...
... for the control of glucose metabolism. It ... of Langerhans as the precursor, proinsulin, which is ... are secreted in equimolar amounts into the portal ... of two polypeptide chains, the A-chain and B-chain ...
ENA Screen EIA Auto-Immune Markers 012-MDKES1 Extractable Nuclear Antigens...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: